GENE ONLINE|News &
Opinion
Blog

2025-11-28|

Porin A and α/β-Hydrolase Identified as Key Proteins in Hemolytic Activity of Bartonella bacilliformis

by GOAI
Share To

Researchers have identified two key proteins, Porin A and an α/β-hydrolase enzyme, as central to the hemolytic activity of *Bartonella bacilliformis*, the bacterium responsible for Carrión’s disease. The study highlights these molecular components as both necessary and sufficient for the destruction of red blood cells, a hallmark of the disease. This discovery sheds light on the mechanisms underlying the pathogen’s ability to cause severe anemia in infected individuals.

The findings provide insight into how *Bartonella bacilliformis* interacts with host cells during infection. Porin A and the α/β-hydrolase enzyme were shown to play critical roles in facilitating hemolysis, or red blood cell rupture. Researchers conducted experiments demonstrating that these proteins are essential for this process, which contributes to the progression of Carrión’s disease. The study offers a deeper understanding of bacterial pathogenesis and may inform future research into potential therapeutic interventions targeting these specific proteins.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: November 28, 2025

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
LATEST
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
How AWS Cloud Is Transforming Global Smart Healthcare and Trusted Research Environments
2025-12-03
MedTex 2025: Taiwan as Gateway for AI-Driven Medical Innovation and Global Capital
2025-12-03
FDA CBER Director Vinay Prasad Issues November 2025 Memo Addressing Vaccine Development and Regulatory Challenges
2025-12-03
FDA to Review 16 Drug Applications Including 8 New Molecular Entities by Year-End
2025-12-03
Stephen Durso Named CEO of Altimmune Inc. as Vipin Garg Steps Down
2025-12-03
Janux Therapeutics Shares Halve Despite Positive Phase I Trial Results for Solid Tumor Therapy
2025-12-03
EVENT
2025-12-06
The 67th ASH Annual Meeting and Exposition
Orlando, Florida, USA
2025-12-04
2025 Healthcare+ Expo Taiwan
Taipei, Taiwan
Scroll to Top